PeptideDB

Sivelestat sodium

CAS No.: 150374-95-1

Sivelestat, an inhibitor of human neutrophil elastase, is used in the treatment of acute respiratory failure. Preliminar
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Sivelestat, an inhibitor of human neutrophil elastase, is used in the treatment of acute respiratory failure. Preliminary studies show Sivelestat may improve neuropathic pain.
Synonyms ONO 5046, LY-544349, Sivelestat sodium salt, ONO-5046, ONO5046, 西维来司钠, LY544349, LY 544349
molecular weight 456.44
Molecular formula C20H21N2NaO7S
CAS 150374-95-1
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility DMSO: Soluble H2O: Insoluble
References 1. Xiao XG, Zu HG, Li QG, Huang P. Sivelestat sodium hydrate attenuates acute lung injury by decreasing systemic inflammation in a rat model of severe burns. Eur Rev Med Pharmacol Sci. 2016 Feb;20(3):528-36. PubMed PMID: 26914130. 2. Wang J, Dai XJ, Zhang YF, Zhong DF, Wu YL, Chen XY. [Simultaneous determination of sivelestat and its metabolite XW-IMP-A in human plasma using HPLC-MS/MS]. Yao Xue Xue Bao. 2015 Oct;50(10):1318-23. Chinese. PubMed PMID: 26837180. 3. Yamada K, Kobayashi H, Bo R, Takahashi T, Hasegawa Y, Nakamura M, Ishige N, Yamaguchi S. Elevation of pivaloylcarnitine by sivelestat sodium in two children. Mol Genet Metab. 2015 Nov;116(3):192-4. doi: 10.1016/j.ymgme.2015.09.009. Epub 2015 Sep 26. PubMed PMID: 26428892. 4. Miyoshi S, Ito R, Katayama H, Dote K, Aibiki M, Hamada H, Okura T, Higaki J. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Des Devel Ther. 2014 Sep 2;8:1211-9. doi: 10.2147/DDDT.S68030. eCollection 2014. PubMed PMID: 25214765; PubMed Central PMCID: PMC4159222.